FDA Warns Ferring, Says Firmagon Sales Pitch Is Misleading

Law360, Washington (April 13, 2012, 6:01 PM EDT) -- Ferring Pharmaceuticals Inc. was hit with a warning letter from the U.S. Food and Drug Administration, posted to the agency's website Friday, for making unsubstantiated claims that its prostate cancer treatment could be used as an early-stage therapy.

The letter focused on an electronic Ferring sales aid for Firmagon, which is approved to treat advanced prostate cancer. The iPad sales aid misbranded Firmagon as a preradiation, or neoadjuvant, treatment and a potential therapy for elevated prostate specific antigen, or PSA, according to the FDA.

But clinical...
To view the full article, register now.